Sign in

Matthew Baggott

@mattbagg.eurosky.social
1K followers 918 following 135 posts

Scientist, CEO @ Tactogen

PostsRepliesMedia
Reposted by Matthew Baggott
Mark Baxter 🏳️‍🌈🧂 @markgbaxter.bsky.social · 24/09/2026
If you work with international personnel, you may want to comment on this proposed rule change that would put visa holders out of status immediately (instead of after a 60 day grace period) when their employment ends keepthe60days.com
keepthe60days.com
Keep the 60 Days: H-1B, E-3, L-1, O-1 & TN grace period
DHS proposes ending the 60-day grace period after a layoff for H-1B, E-3, L-1, O-1 and TN visa holders. Comment on USCIS-2026-0364 before November 10, 2026.
02839
Matthew Baggott @mattbagg.eurosky.social · 23/09/2026
To Assembly, From Disassembly: In re L3-37, Continuity of Synthetic Personhood and the Right to Morphological Freedom
110
Matthew Baggott @mattbagg.eurosky.social · 23/09/2026
The Force Is Strong with This One: Pharmacological Characterization of Halo- and Alkoxy-Midi-Lorian Analogues in a Womp-Rat Model of Force-Mediated Suggestibility
031
Matthew Baggott @mattbagg.eurosky.social · 14/09/2026
Shouldn't last Monday's article from FDA staff have had a notice that “U.S. Government-authored contributions are in the public domain in the U.S.” rather than a copyright? It's not great when regulators speak via privately owned, paywalled channels.
021
Reposted by Matthew Baggott
Psychedelic Brain Science @psychedbrainsci.bsky.social · 11/09/2026
The FDA Psychedelic Hearing is next week… here is everything you need to know. Event takes place virtually or in person on September 14, 11:30-4:30pm ET.
122
Matthew Baggott @mattbagg.eurosky.social · 09/09/2026
Mike Davis has been announced as head of FDA's CDER. He is a well-regarded FDA veteran who was CMO at the nonprofit psychedelic company Usona for about 3 years. www.hhs.gov/press-room/h...
hhs.gov
HHS Announces Key Leadership Selections at FDA to Promote Innovation, Reform, and National Health Priorities
The U.S. Department of Health and Human Services today announced the selection of four senior leaders at the U.S. Food and Drug Administration.
022
Matthew Baggott @mattbagg.eurosky.social · 05/09/2026
www.nytimes.com/2026/09/04/o...
010
Matthew Baggott @mattbagg.eurosky.social · 04/09/2026
www.health.govt.nz/news/two-psy...
health.govt.nz
Two psychiatrists granted approval to prescribe medicinal MDMA for PTSD
Medsafe has approved two New Zealand psychiatrists to prescribe pharmaceutical-grade MDMA as part of a treatment programme for eligible adults with post-traumatic stress disorder (PTSD).
000
Matthew Baggott @mattbagg.eurosky.social · 03/09/2026
This is a genuinely exciting (mouse) result that may address a big unmet need and seemingly works with non psychedelic 2A agonists (tabernanthalog worked). www.science.org/doi/10.1126/...
science.org
Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling, often irreversible toxicity that affects millions of patients, limits life-saving cancer therapy, and lacks proven treatment. In this ...
182
Reposted by Matthew Baggott
Tressie McMillan Cottom @tressiemcphd.bsky.social · 31/08/2026
58741
Matthew Baggott @mattbagg.eurosky.social · 27/08/2026
Cool work. Sounds to me like much of the novelty is in tracking the neural mechanisms. There was a lot of cool 50s era behaviorist research developing similar assignments. A few examples follow...
120
Reposted by Matthew Baggott
PAIN @painthejournal.bsky.social · 26/08/2026
Arnold et al. find that RCTs investigating neuropathic pain often contain psychiatric-related exclusion criteria, potentially reducing the generalizability to a substantial population subset that experiences comorbid psychiatric disorders #PAIN bit.ly/4coVqGs
012
Reposted by Matthew Baggott
AT Protocol Developers @atproto.com · 20/08/2026
The most significant extension to the protocol since launch—atproto spaces—is now officially alpha software you can start testing with. Here's more about the goals and how to start testing. atproto.com/blog/atproto...
atproto.com
The Atproto Spaces Alpha is Live
Atproto Spaces, formerly known as “the permissioned data protocol,” is a new extension to atproto that enables non-public data. The alpha is now officially open. Here’s how to develop with it and what to expect as we work towards the full release.
26340123
Matthew Baggott @mattbagg.eurosky.social · 19/08/2026
www.biorxiv.org/content/10.6...
biorxiv.org
Tuning in together: LSD enhances inter-brain synchrony and felt connectedness in romantic couples
Social connection is fundamental to human wellbeing. Serotonergic psychedelics such as lysergic acid diethylamide (LSD) acutely heighten subjective connectedness, yet their effects on real-time social...
010
Reposted by Matthew Baggott
Scott Thompson, PhD @sthom003.bsky.social · 13/08/2026
My hypothesis is that these findings reflect more of a threshold phenomenon in which you need to get a certain number of serotonin receptors activated and beyond that there’s no additional benefit.
052
Reposted by Matthew Baggott
Iris van Rooij 💭 @irisvanrooij.bsky.social · 05/08/2026
If you would like to teach theoretical modeling skills to your psychology or cognitive science students, or would like to learn these skills yourself, check out our open online textbook: computationalcognitivescience.github.io/lovelace/
Book cover: orange/yellow background and generated tree in front. Artwork by Danielle Navarro
29139
Matthew Baggott @mattbagg.eurosky.social · 07/08/2026
thehill.com/opinion/heal...
thehill.com
HHS should protect payments to clinical trial participants
The HHS Office of Inspector General is seeking public comment on whether to protect payments to clinical trial participants, a move supported by research showing that compensating individuals—inclu…
000
Matthew Baggott @mattbagg.eurosky.social · 02/08/2026
This is an insightful conversation decodingbio.substack.com/p/a-conversa...
decodingbio.substack.com
A Conversation with Jack Scannell: The Intractable ‘Sociotechnical’ Problems of Drug Discovery and Development, Genetic Triumphalism and Predictive Validity
Jack is one of the sharpest thinkers on the pharmaceutical industry, with a talent for coining terms that then propagate among industry insiders and into wider tech circles.
000
Matthew Baggott @mattbagg.eurosky.social · 21/07/2026
Lilly is buying AtaiBeckley in the largest psychedelics deal yet. I wrote a few thoughts on Linkedin on what the deal actually commits it to, what it leaves out, and what the rest of the year will tell us. www.linkedin.com/pulse/what-l...
000
Matthew Baggott @mattbagg.eurosky.social · 26/06/2026
This project of early-career biologists curating and commenting on preprints looks cool. prelights.biologists.com/about-us/
prelights.biologists.com
About us - preLights
Welcome to preLights, the preprint highlights service run by the biological community and supported by The Company of Biologists. What is preLights? As the number of preprints grows, it will become in...
021
Reposted by Matthew Baggott
anil oza @aniloza.bsky.social · 25/06/2026
Looks like groups outside the scientific community are commenting in higher numbers Day 18: 35,323 total comments, 17,458 mention science, 19,135 mention research
Graph showing increase in the number of comments on OMB proposal over time
33513
Reposted by Matthew Baggott
Caswell Barry @caswell.bsky.social · 23/06/2026
Really excited about this work with the awesome Will de Cothi & @shipleysj.bsky.social, out in Nature Reviews Neuroscience. We propose acetylcholine is an analogue of dopamine — tracking not reward prediction errors but state-transition prediction errors. doi.org/10.1038/s41583-026-01058-w
25425
Reposted by Matthew Baggott
jordan! @jordanjamboree.pittbert.gay · 22/06/2026
Instead of giving clicks to the #1 Newspaper that supported the invasion of Iraq, maybe look at this article about how dangerous American pickup trucks are by my lovely co-host, who never once laundered the American invasion of Iraq
229582
Matthew Baggott @mattbagg.eurosky.social · 18/06/2026
Important preprint on the risks of ibogaine in clinics (19,071 patients, 11 clinics): all 6 deaths within 72h were in opioid-detox patients, 0 among 8,689 non-SUD patients, supporting the idea that risk clusters in opioid detox not the TBI/PTSD indications. www.researchsquare.com/article/rs-9...
researchsquare.com
Indication-stratified mortality risk of ibogaine treatment under contemporary safety protocols: a multisite analysis of 19,071 patients and updated systematic review of fatalities
Ibogaine has shown early therapeutic promise for substance use disorders (SUD) and post-traumatic stress disorder in veterans, but concerns about treatment-associated cardiac arrhythmia and death have...
140
Matthew Baggott @mattbagg.eurosky.social · 11/06/2026
If you developed a drug that successfully slowed human aging, how would you actually get it approved by the FDA? Here are my notes on what the FDA signaled at the recent Reagan-Udall Foundation meeting. www.linkedin.com/pulse/roadma...
000
Reposted by Matthew Baggott
Rachel Nuwer @rachelnuwer.bsky.social · 11/06/2026
Science mystery! Nearly everyone, everywhere, veers left when walking. Why??? www.nytimes.com/2026/06/10/s... @nytimes.com
nytimes.com
Nearly Everyone, Everywhere, Veers Left When Walking
151
Matthew Baggott @mattbagg.eurosky.social · 09/06/2026
Steve Cohen (TN-9) yesterday introduced the Controlled Substances Act (CSA) Clarification in Sciences Act to update the 1970 CSA, which is greatly needed. Text is not yet available but will be here www.congress.gov/bill/119th-c...
congress.gov
100
Reposted by Matthew Baggott
Laura Dattaro @ldattaro.bsky.social · 04/06/2026
I wrote about the new rule proposing political oversight of every form of federal grant-making and what it means, legally, for OMB to do this. Wild it's gotten nearly 5k comments in < a week. Thanks to Carrie Wolinetz, @cdelawalla.bsky.social for their insights cen.acs.org/policy/resea...
cen.acs.org
White House move to step up political role in US research sparks alarm
An Office of Management and Budget proposal would insert political oversight into federal grant decisions, downgrade peer review, and expose all grants to termination without cause
01815
Matthew Baggott @mattbagg.eurosky.social · 02/06/2026
OMB has proposed a sweeping overhaul of how federal research grants are awarded, terminated, and funded. I just posted my planned comments on LinkedIn in the hope it will make it easier for others to submit their own comments. www.linkedin.com/pulse/ombs-p...
110
Reposted by Matthew Baggott
Dr. Lucky Tran @luckytran.com · 02/06/2026
Incredible! Scientists receive a rare standing ovation after announcing that a new treatment can double the survival time for pancreatic cancer, the deadliest cancer which was once considered “undruggable.” When we fund and support science, we can achieve anything! (Video: Dr. Wish Dhillon)
266147633496
Reposted by Matthew Baggott
Meike Ramon @meikeramon.bsky.social · 21/05/2026
Science Needs 3rd Spaces We envision scientific third spaces as “collaborative hubs where researchers, artists, engineers, and practitioners co-develop methods, share resources, and pursue projects driven by curiosity". authors.elsevier.com/sd/article/S...
2339
Reposted by Matthew Baggott
Sam Ottewill-Soulsby @samottewillsoulsby.bsky.social · 17/03/2026
Going through an issue of the TLS from last December, I find a philosophy pun courtesy of Nigel Warburton that surely deserves wider currantsy.
Yet, although he imagined the possibility of a serious and good philosophical work told as a series of jokes, Wittgenstein didn’t think it should be a series of pithy sayings. He made this point with an aphorism: "Raisins may be the best part of a cake; but a bag of raisins is not better than a cake.” (We might call this Wittgenstein's “Critique of Pure Raisin”.)
720156
Reposted by Matthew Baggott
Patrick Mineault @patrickmineault.bsky.social · 04/05/2026
Do you think that the canonical cortical circuit is complicated? It's so much worse than that! Overlayed on top of the wired connectome, there are *18* different signal-carrying peptides in cortex! Their range is ~similar to the size of a cortical column elifesciences.org/articles/47889 1/
34913
Matthew Baggott @mattbagg.eurosky.social · 01/05/2026
I don't necessarily disagree with the conclusions but I'm very surprised they aren't reporting rate pressure product, the conventional surrogate for myocardial oxygen demand. My guess is this will change a bit in review. www.medrxiv.org/content/10.6...
medrxiv.org
Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations
Background: Psilocybin is increasingly studied as a therapeutic for psychiatric and neurologic conditions, yet comprehensive cardiovascular safety data are limited. Current trials often exclude indivi...
000
Reposted by Matthew Baggott
Manoj Doss not exist @manojdoss.bsky.social · 30/04/2026
So entropy isn't a great index of psychedelic fx, DMN isn't selectively disrupted by psychedelics (see last post), & psychedelics don't selectively facilitate bottom-up processing (there are several references on this I'd be happy to share), so what's left for EBH/REBUS? 10/10
142
Reposted by Matthew Baggott
Dan Quintana @dsquintana.bsky.social · 29/04/2026
Selecting an effect size for power analysis is hard. Many researchers fall back on Cohen's thresholds, but they have no empirical basis and vary wildly by field. Our new paper offers a better option: field-specific effect size distributions built from meta-analytic data doi.org/10.3758/s134...
Abstract
Effect sizes are useful for understanding the magnitude of study results and for planning new studies via power analysis.
However, despite their wide usage, effect sizes are often misinterpreted. This is mostly due to an over-reliance on general
effect size benchmarks that were not intended for broad application across diverse research fields. Inaccurate effect size
interpretations can lead to incorrect conclusions about the magnitude of study results and incorrect sample size estimates,
thereby increasing the likelihood of false-positive results. This article introduces the ESDist R package, which is designed
to calculate empirically derived effect-size benchmarks or a range of reliably detectable empirical effect sizes for a specific
research question or field of interest by computing effect size distributions (ESDs). This package can be used on data that
can be easily extracted from pre-existing meta-analyses to help researchers more accurately plan new studies or to better
understand how an individual study might relate to other studies in their field. ESDist includes a set of features that make it
easy to use in a priori power analysis. Moreover, the package includes a feature for estimating effect size benchmarks that
account for publication bias and are weighted by effect sizes' variances, which addresses existing limitations of using ESDs
for study planning or interpretation.
316175
Reposted by Matthew Baggott
Alex Kwan @alexkwan.bsky.social · 27/04/2026
Excited to share an early look at psilo-seq, a web portal for exploring our lab’s single-nucleus RNA-seq data in mice following psychedelic treatment.
13115
Matthew Baggott @mattbagg.eurosky.social · 28/04/2026
www.nature.com/articles/s41...
nature.com
Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy ...
Neuropsychopharmacology - Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind,...
041
Matthew Baggott @mattbagg.eurosky.social · 28/04/2026
First time I've ever saved a post
020
Reposted by Matthew Baggott
Ricard Solé @ricardsole.bsky.social · 27/04/2026
What patterns can chemistry grow when left to organize itself? I got "chemical gardens" at home, with mineral “plants” blooming inside a flask as self-organizing worlds emerging from simple ingredients. Inspired by: www.damtp.cam.ac.uk/user/gold/pd... @leecronin.bsky.social @marktas.bsky.social
0291
Reposted by Matthew Baggott
Manoj Doss not exist @manojdoss.bsky.social · 27/04/2026
I'm looking for a post-bac research assistant to help run our studies on the impact of psychedelics on memory! Preferably with an interest in cognitive neuroscience (not just psychedelics or clinical research) and knowledge of coding/data analysis. utaustin.wd1.myworkdayjobs.com/UTstaff/job/...
utaustin.wd1.myworkdayjobs.com
Research Associate I
Job Posting Title: Research Associate I ---- Hiring Department: Department of Psychiatry ---- Position Open To: All Applicants ---- Weekly Scheduled Hours: 40 ---- FLSA Status: Exempt from FLSA ---- E...
063
Reposted by Matthew Baggott
Nature @nature.com · 26/04/2026
Real-world data reveal that cooperation continually falls and rebounds. Motivation to cooperate must therefore be actively renewed rather than assumed to sustain itself go.nature.com/4tvFx7I
go.nature.com
Human cooperation undergoes constant breakdown and repair
Real-world data reveal that cooperation continually falls and rebounds. Motivation to cooperate must therefore be actively renewed rather than assumed to sustain itself.
09531
Matthew Baggott @mattbagg.eurosky.social · 23/04/2026
Been wondering how long the DEA would get to stall on this. Good stats are hard to come by but the estimate is 40% of drug arrests are for cannabis possession. Few of these are federal cases and states have their own drug laws, so these good steps do not automatically help vs local injustice.
121
Matthew Baggott @mattbagg.eurosky.social · 23/04/2026
My thoughts on why there were so many AI companies announcing biotech projects this month: www.linkedin.com/pulse/why-bi...
011
Reposted by Matthew Baggott
R Consortium @rconsortium.bsky.social · 22/04/2026
R/Medicine Hackathon is tomorrow! Focusing on the {teal} package, a framework for building interactive exploratory data analysis applications in clinical trials. Beginners welcome, registration for R/Medicine required. Sign up, prep, and all the deets here: rconsortium.github.io/RMedicine_we...
R/Medicine coming May 5-8 - Hackathon tomorrow April 23
053
Reposted by Matthew Baggott
Arthur Prat @arthurpr4t.bsky.social · 21/04/2026
The "Version of Record" of my paper with Mike Woodford is finally there. I am very glad with this paper that points to new laws of psychophysics, which we derived from a carefully considered principle of endogenous efficient coding.
elifesciences.org
Endogenous precision of the number sense
A theory of efficient coding wherein the precision of representations is endogenous, task-dependent, and prior-dependent predicts scaling laws for imprecision and is supported by numerosity perception...
1186
Reposted by Matthew Baggott
David Weiskopf believes in you @dave.bzky.team · 21/04/2026
Had a great time today talking transportation with @jeffreytumlin.bsky.social, Darwin Moosavi, and @francessawyer.bsky.social. Big takeaways: - SAVE TRANSIT by voting yes on the two Bay Area transit measures - Policy is personnel: focus on office-holders, not just projects or policies
Photo of the people listed in the post, including me, doing a "I once ate a meatball *this* big" gesture in front of signs about our panel.
1307
Reposted by Matthew Baggott
Manoj Doss not exist @manojdoss.bsky.social · 17/04/2026
Now that it has been out for a week, I thought I’d address a few strange takes regarding our recent mega-analysis on the effects of psychedelics on brain function (specifically, resting-state functional connectivity). 1/15 www.nature.com/articles/s41...
nature.com
An international mega-analysis of psychedelic drug effects on brain circuit function - Nature Medicine
Analysis of neuroimaging datasets across five major psychedelics revealed a shared brain signature and provides a comprehensive insight into how these drugs reorganize brain architecture.
1115
Matthew Baggott @mattbagg.eurosky.social · 14/04/2026
Looking forward to this book on Sol Snyder: bookshop.org/p/books/the-...
bookshop.org
The Madness Pill: One Doctor's Quest to Understand Schizophrenia
One Doctor's Quest to Understand Schizophrenia
020